Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
STIMATE vs DESMODA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Desmopressin acetate is a synthetic analog of the natural pituitary hormone 8-arginine vasopressin (ADH). It acts as a V2 receptor agonist in the renal collecting ducts, increasing water permeability and promoting water reabsorption, thereby reducing urine output. It also increases plasma levels of von Willebrand factor and factor VIII via V2 receptor stimulation on endothelial cells.
Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone, ADH) that acts on V2 receptors in renal collecting ducts, increasing water reabsorption and reducing urine output. It also raises plasma levels of factor VIII and von Willebrand factor via V2 receptor stimulation on endothelial cells.
Central diabetes insipidus,Primary nocturnal enuresis,Hemophilia A with factor VIII levels >5%,von Willebrand disease (type 1)
Central diabetes insipidus,Primary nocturnal enuresis,Hemophilia A with factor VIII levels >5%,von Willebrand disease (type I)
Intranasal: 1 spray (1.5 mg) into one nostril, 1 hour prior to voiding or on awakening for bedwetting; maximum 2 sprays per day.
10 mg orally once daily
Terminal elimination half-life is approximately 3-4 hours in healthy adults, but may be prolonged in patients with renal impairment or in older adults.
Terminal half-life: 8-12 hours; extended in renal impairment (up to 24 hours).
Not extensively metabolized; primarily excreted unchanged in urine. A small fraction may be metabolized by liver or kidney peptidases.
Metabolized primarily by reduction of disulfide bonds; not extensively metabolized by CYP450 enzymes.
Desmopressin is primarily excreted renally, with approximately 60-70% of the dose recovered unchanged in urine within 24 hours. The remaining fraction is metabolized hepatically and eliminated via feces.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites.
Desmopressin exhibits low protein binding, approximately 1-2%, primarily to albumin.
95%; primarily binds to albumin and alpha-1-acid glycoprotein.
Volume of distribution is 0.2-0.4 L/kg, indicating distribution primarily in extracellular fluid.
Vd: 0.5-0.7 L/kg; indicates moderate tissue distribution.
Intranasal: 10-20%; Oral: 5-10% due to extensive first-pass metabolism.
Oral: 85-90% with food; 70-80% fasting.
No specific adjustment; caution in severe impairment (e GFR <15 m L/min).
No adjustment required for GFR ≥30 m L/min; contraindicated if GFR <30 m L/min
No specific adjustment; limited data in Child-Pugh C; use cautiously.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 5 mg once daily; Child-Pugh C: contraindicated
Children ≥6 years: same as adult; intranasal 1 spray (1.5 mg) 1 hour before bedtime. Do not exceed 2 sprays per day.
Not recommended for use in pediatric patients
Use caution due to risk of hyponatremia and hypertension; start at lowest effective dose.
Initiate at 5 mg once daily; monitor renal function closely
No FDA black box warning exists for STIMATE.
No FDA black box warning.
Hyponatremia and fluid overload with water intoxication,Seizures due to hyponatremia,Thrombotic events (in patients with predisposing factors),Caution in patients with cystic fibrosis, coronary artery disease, or hypertension,Risk of arterial or venous thrombosis, especially with desmopressin treatment for bleeding disorders,Elderly patients at increased risk of hyponatremia
Risk of hyponatremia and seizures, especially in children and patients on fluid overload,Fluid restriction should be observed,Use with caution in patients with electrolyte imbalance, renal impairment, cystic fibrosis, or coronary artery disease,Avoid in patients with primary polydipsia
Hypersensitivity to desmopressin or any component,Moderate to severe renal impairment (Cr Cl <50 m L/min),Hyponatremia or history of hyponatremia,Known platelet-type von Willebrand disease (pseudo-von Willebrand disease),Unstable angina, decompensated heart failure, or severe coronary artery disease
Hypersensitivity to desmopressin or any component,Moderate to severe renal impairment (Cr Cl <50 m L/min),Hyponatremia or history of hyponatremia,Primary polydipsia,Patients on diuretics or other drugs that increase risk of hyponatremia
No specific food interactions. However, avoid excessive fluid intake (more than needed to satisfy thirst) while taking STIMATE to reduce risk of water intoxication and hyponatremia. For patients with nocturnal enuresis, restrict fluids 1 hour before bedtime.
Avoid concurrent intake of large volumes of water or hypotonic fluids. Alcohol may reduce antidiuretic effect. Caffeine may increase urine output. Grapefruit juice may enhance absorption of oral formulations.
Pregnancy Category X. Desmopressin (STIMATE) is contraindicated in pregnancy due to risk of uterine contractions and potential fetal harm. First trimester: No adequate studies; theoretical risk of teratogenicity. Second trimester: Avoid due to risk of preterm labor. Third trimester: May induce premature labor; use only if clearly needed for diabetes insipidus.
Desmoda is contraindicated in pregnancy. First trimester: Risk of major congenital malformations (neural tube defects, cardiovascular anomalies) due to folate antagonism. Second/Third trimester: Fetal growth restriction, oligohydramnios, premature closure of ductus arteriosus (if NSAID component).
Desmopressin is excreted in breast milk in low amounts; M/P ratio not established. No adverse effects reported in infants. Use with caution, especially in nursing mothers with preeclampsia due to potential for water intoxication.
Excreted in breast milk. M/P ratio not established. Avoid breastfeeding due to potential for serious adverse reactions (e.g., folate deficiency, kernicterus) in the infant.
Increased plasma volume and enhanced renal clearance in pregnancy may reduce desmopressin concentrations; dose adjustments may be required. Monitor clinical response and adjust dose based on urine output and plasma sodium. No standard dose adjustment; individualize therapy.
Contraindicated in pregnancy. No dose adjustment recommended; avoid use. If accidental exposure occurs, discontinue immediately and initiate folate rescue therapy.
STIMATE (desmopressin acetate) is a synthetic analog of vasopressin used for diabetes insipidus and nocturnal enuresis. Monitor for hyponatremia, especially in patients with increased fluid intake, elderly, or those on medications that increase ADH (e.g., SSRIs, NSAIDs). Use with caution in patients with renal impairment, cardiovascular disease, or cystic fibrosis. Avoid use in patients with primary polydipsia or uncontrolled hypertension. For nocturnal enuresis, limit fluid intake 1 hour before dose. Start at lowest effective dose and titrate. Can be administered intranasally, orally, or intravenously. Intranasal route is not recommended for infants due to variable absorption.
Desmopressin is a synthetic analog of vasopressin used for central diabetes insipidus and nocturnal enuresis. Monitor serum sodium, especially in elderly or patients with fluid/electrolyte imbalance. Avoid in patients with hyponatremia or renal impairment. Tachyphylaxis may occur; dose adjustment may be needed. Intranasal route may be less reliable due to mucosal variability.
Take STIMATE exactly as prescribed; do not increase dose or frequency without consulting your doctor.,For nocturnal enuresis: avoid drinking fluids 1 hour before bedtime and use the bathroom before going to sleep.,Report signs of hyponatremia: headache, nausea, vomiting, confusion, muscle cramps, weakness, or seizures.,Do not use STIMATE if you have allergies to desmopressin or any ingredient in the formulation.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease, heart disease, or cystic fibrosis.,Store STIMATE at room temperature away from moisture and heat; do not freeze.,For intranasal spray: prime the pump before first use and when not used for 7 days. Blow nose gently before use and do not sniff deeply after spraying.,Do not share your medication with others.
Take exactly as prescribed; do not exceed dose to avoid water intoxication.,Fluid restriction is critical: limit fluid intake for 1-2 hours after dosing, especially at night.,Report symptoms of hyponatremia: headache, nausea, vomiting, confusion, seizures.,For enuresis, take last dose at bedtime; avoid drinking 1 hour before and 8 hours after.,Intranasal formulations: administer alternately in each nostril; clear nasal passages before use.
"Lumacaftor, a component of the cystic fibrosis transmembrane conductance regulator (CFTR) corrector therapy, is a strong inducer of cytochrome P450 (CYP) 3A4 enzymes. Concurrent administration with norgestimate, a progestin component of oral contraceptives that is metabolized primarily by CYP3A4, can significantly reduce norgestimate plasma concentrations. This reduction may diminish the contraceptive efficacy and potentially lead to unintended pregnancy, as well as reduced therapeutic effects for other indications of norgestimate."
"Norgestimate, a progestin component of oral contraceptives, may induce the activity of UDP-glucuronosyltransferases (UGTs), particularly UGT1A1 and UGT2B7, which are involved in the glucuronidation and clearance of miglustat. This enzyme induction can decrease miglustat plasma concentrations, potentially reducing its therapeutic efficacy in treating Gaucher disease or Niemann-Pick type C disease. The clinical outcome could be diminished disease control, requiring dose adjustments or alternative therapy."
"Oxcarbazepine, a potent inducer of cytochrome P450 3A4 (CYP3A4) and uridine diphosphate glucuronosyltransferases (UGTs), significantly decreases the serum concentration of norgestimate by enhancing its hepatic metabolism. This metabolic induction converts norgestimate to less active metabolites, reducing its contraceptive efficacy. Clinically, this interaction may lead to unintended pregnancy in women using hormonal contraceptives containing norgestimate, as well as potential breakthrough bleeding or irregular menstrual cycles."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about STIMATE vs DESMODA, answered by our medical review team.
STIMATE is a Antidiuretic Hormone Analog that works by Desmopressin acetate is a synthetic analog of the natural pituitary hormone 8-arginine vasopressin (ADH). It acts as a V2 receptor agonist in the renal collecting ducts, increasing water permeability and promoting water reabsorption, thereby reducing urine output. It also increases plasma levels of von Willebrand factor and factor VIII via V2 receptor stimulation on endothelial cells.. DESMODA is a Antidiuretic Hormone Analog that works by Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone, ADH) that acts on V2 receptors in renal collecting ducts, increasing water reabsorption and reducing urine output. It also raises plasma levels of factor VIII and von Willebrand factor via V2 receptor stimulation on endothelial cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between STIMATE and DESMODA depend on the specific clinical indication. These are both Antidiuretic Hormone Analog agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of STIMATE is: Intranasal: 1 spray (1.5 mg) into one nostril, 1 hour prior to voiding or on awakening for bedwetting; maximum 2 sprays per day.. The standard adult dose of DESMODA is: 10 mg orally once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between STIMATE and DESMODA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. STIMATE is classified as Category C. Pregnancy Category X. Desmopressin (STIMATE) is contraindicated in pregnancy due to risk of uterine contractions and potential fetal harm. First trimester: No adequate studies; the. DESMODA is classified as Category C. Desmoda is contraindicated in pregnancy. First trimester: Risk of major congenital malformations (neural tube defects, cardiovascular anomalies) due to folate antagonism. Second/Th. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.